RadNet Announces a Proposed Refinancing Transaction for its $611 Million Senior Secured Term Loan and $195 Million Senior Secured Revolving Credit Facility

April 6, 2021

RadNet, Inc. a provider of high-quality, cost-effective diagnostic imaging services through a network of owned and/or operated outpatient imaging centers, today announced a proposed refinancing transaction for its existing senior secured first-lien term loan, which had a balance of $611 million as of December 31, 2020, and its $195 million senior secured revolving credit facility, which was undrawn as of year-end 2020.

RadNet seeks to replace these facilities with a proposed seven-year $675 million senior secured term loan B facility and a five-year $195 million senior secured first-lien revolving credit facility. In addition to repaying the existing $611 million senior secured first-lien term loan, the proceeds are expected to pay estimated fees and expenses and fund cash to the Company’s balance sheet.

The proposed refinancing transaction would be subject to negotiations with lenders and market and other conditions. As such, there can be no assurance that the company will complete a refinancing transaction on terms that are favorable to RadNet or its investors. RadNet may engage from time to time in discussions with creditors of RadNet, as well as their respective advisors, as RadNet pursues the potential refinancing transaction.

Mark Stolper, Executive Vice President and Chief Financial Officer said, commented, “We have publicly discussed in recent quarters the possibility of extending the maturity of our debt capital, lowering our cost of capital, and provide the Company further operating flexibility through refinancing our current senior secured debt.”

He concluded, “After having consulted with our financial advisors, we expect to launch a refinancing transaction designed to replace our current senior secured first-lien term loan and revolving credit facility with similar debt facilities, subject to market and other conditions, extend current maturities and fund an additional cash balance which we can use to further grow our business. If successful, we currently expect to consummate a transaction this month.”

SourceRadNet

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”